About ContraFect Corp (NASDAQ:CFRXU)
ContraFect Corporation (ContraFect ) is a biotechnology company. The Company is focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. It intends to address drug-resistant infections using its therapeutic product candidates from its lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). Its product candidates are CF-301, a lysin for the treatment of Staph aureus bacteremia, and CF-404, a combination of mAbs for the treatment of life-threatening seasonal and pandemic varieties of influenza. CF-301 and CF-302 are bacteriophage lysins with potent activity against Staph aureus infections.
Industry, Sector and Symbol:
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Sector: Biotechnology & Medical Research - NEC
- Symbol: NASDAQ:CFRXU
- CUSIP: N/A
- Web: www.contrafect.com
- Outstanding Shares: 24,740,000
Frequently Asked Questions for ContraFect Corp (NASDAQ:CFRXU)
What is ContraFect Corp's stock symbol?
ContraFect Corp trades on the NASDAQ under the ticker symbol "CFRXU."
Who are some of ContraFect Corp's key competitors?
Some companies that are related to ContraFect Corp include GTx (GTXI), Nabriva Therapeutics AG (NBRV), OncoMed Pharmaceuticals (OMED), CASI Pharmaceuticals (CASI), Zynerba Pharmaceuticals (ZYNE), Pluristem Therapeutics (PSTI), Merrimack Pharmaceuticals (MACK), Organovo Holdings (ONVO), Curis (CRIS), Silence Therapeutics plc (SLN), Advaxis (ADXS), Compugen (CGEN), Oramed Pharmaceuticals (ORMP), CTI BioPharma Corp. (CTIC), Eiger BioPharmaceuticals (EIGR), ArQule (ARQL), aTyr Pharma (LIFE) and BioLineRx (BLRX).
Who are ContraFect Corp's key executives?
ContraFect Corp's management team includes the folowing people:
- Steven C. Gilman Ph.D., Chairman of the Board, Chief Executive Officer (Age 64)
- Joshua B. Muntner, Co-Chief Executive Officer, Senior Vice President - Business Development (Age 48)
- Michael Messinger CPA, Co-Chief Executive Officer, Vice President - Finance (Age 42)
- Roger Pomerantz M.D., Vice Chairman of the Board (Age 60)
- Lisa R. Ricciardi, Chief Operating Officer, Director (Age 56)
- Nancy Dong, Vice President, Controller
- Cara M. Cassino M.D., General Counsel, Secretary, Chief Medical Officer (Age 55)
- Natalie Bogdanos, General Counsel and Corporate secratary (Age 46)
- Sol J. Barer Ph.D., Lead Independent Director (Age 69)
- Isaac Blech, Independent Director (Age 67)
How do I buy ContraFect Corp stock?
Shares of ContraFect Corp can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ContraFect Corp's stock price today?
One share of ContraFect Corp stock can currently be purchased for approximately $6.11.
How big of a company is ContraFect Corp?
ContraFect Corp has a market capitalization of $117.86 million.
How can I contact ContraFect Corp?
ContraFect Corp's mailing address is 28 Wells Ave Ste 3, YONKERS, NY 10701-7045, United States. The biotechnology company can be reached via phone at +1-914-2072300.
MarketBeat Community Rating for ContraFect Corp (NASDAQ CFRXU)MarketBeat's community ratings are surveys of what our community members think about ContraFect Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for ContraFect Corp (NASDAQ:CFRXU) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for ContraFect Corp (NASDAQ:CFRXU)
Analysts' Ratings History for ContraFect Corp (NASDAQ:CFRXU)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for ContraFect Corp (NASDAQ:CFRXU)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for ContraFect Corp (NASDAQ:CFRXU)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for ContraFect Corp (NASDAQ:CFRXU)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for ContraFect Corp (NASDAQ CFRXU)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for ContraFect Corp (NASDAQ:CFRXU)
Latest Headlines for ContraFect Corp (NASDAQ CFRXU)
Financials are not available for this stock.
ContraFect Corp (NASDAQ CFRXU) Chart for Saturday, November, 18, 2017